Food as medicine gains momentum with $328M in startup funding through Q3 2024, up from $276M in 2023, as Biden administration ...

Viridian Therapeutics’ stock jumped Monday after the company unveiled another Phase 3 look at its potential competitor to ...

HRSA on Friday warned Sanofi against implementing its planned rebate model for some of its outpatient drugs under the drug ...

A turbulent 2024 for Neurocrine is ending on a high note, after the biotech won FDA approval to treat congenital adrenal ...

Edgewise Therapeutics’ treatment candidate for several forms of muscular dystrophy has hit the primary endpoint in a ...

Biohaven reports BHV-1300's lowest dose reduced IgG by 60%+ in trial, below analysts' 70-80% target. Drug shows promise for ...

Just days after winning FTC approval to take on three of Catalent’s facilities, Novo Nordisk said it is investing DKK 8.5 ...

Bristol Myers Squibb is ending a pair of cell therapy collaborations with Immatics and nixing a separate agreement with ...

FTC approves Novo Holdings' $16.5B Catalent acquisition. Deal includes selling 3 facilities to Novo Nordisk for $11B, despite ...

Endpoints Weekly covers ASH conference highlights, FDA discussions on Moderna's RSV vaccine safety, Biosecure Act exclusion, and industry updates from biotech leaders.

Organon won a label expansion for the steroid-free topical cream it picked up from its October acquisition of Dermavant.

McKinsey fined $650M for helping boost OxyContin sales, misleading FDA about conflicts. Ex-partner Martin Elling charged with ...